SARS-CoV-2 Spike RBD Antibody [2165]

• Catalog Number: orb1274629
• Category: Antibodies
• Description: SARS-CoV-2 Spike RBD Antibody [2165]
• Clonality: Recombinant
• Isotype: Human IgG1
• Conjugation: Unconjugated
• Reactivity: Virus
• Form/Appearance: Liquid
• Concentration: ≥ 1.0 mg/ml
• Buffer/Preservatives: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
• Purification: > 95% by SDS Page
• Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2). These are made recombinantly in HEK293 cells. The spike RBD is expressed on the surface of SARS-CoV-2.
• Tested applications: ELISA, IHC, NeA
• Application notes: ELISA (Quality Tested by ProSci); N, IHC (Other applications as reported in literature)
• Antibody Type: Primary Antibody
• Clone Number: 2165
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Alternative names: SARS-CoV-2 Spike RBD Antibody, Receptor Binding Do
• Note: For research use only

SARS-CoV-2 Spike RBD Antibody (clone 2165) IHC Data using infected cell pellets.

Coating: Purified Recombinant SARS-CoV-2 Spike RBD, concentration of 1 ul/well, 100 ul/well overnight 2-8 ˚C. Detection: Anti-SARS-CoV-2 RBD (Clone 2165) conjugated to HRP was serially diluted starting at 25 ng/ml down to 0.23 ng/ml, 100 ul/well for 1 hour at 37 ˚C. Substrate: TMB, 100 ul/well for 15 min, at room temperature followed by 450 nm stop solution, 50ul/well.

Anti-SARS-CoV-2 Antibody to the Recepter Binding Domain (RBD) (Clone 2165). Antibody binds to RBD and blocks binding to the ACE2 receptor on coated plates using COVID-19 ImmunoRank Neurilization MICRO-ELISA Assay.